| [1] |
GLOBOCAN 2012: Estimated Cancer Incidence,Mortality and Prevalence Worldwide in 2012[EB/OL]. http://globocan.iarc.fr/ Pages/fact_sheets_cancer.aspx, 2013-12-12.
|
| [2] |
Niu N, Li BL, Liu CY, et al. Combining bevacizumab with endostatin gets better antitumor efficacy in vivo in lung cancer animal model[J]. Zhongguo Fei Ai Za Zhi, 2013, 16(2): 61-6. [牛牛, 李宝兰, 刘朝阳, 等. 重组人血管内皮抑制素联合贝伐珠单抗体 内抑瘤作用的效果及分析[J].中国肺癌杂志, 2013, 16(2): 61-6.]
|
| [3] |
Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer[J]. N Engl J Med, 20 06, 355(24): 2542-50.
|
| [4] |
Yang L, Wang JW, Tang ZM, et al. A Phase Ⅰ clinical trial for recombinant human endostatin[J]. Zhongguo Xin Yao Za Zhi,2004, 13 (6): 548-53.[杨林, 王金万, 汤仲明, 等. 重组人血管内皮抑制素 Ⅰ期临床研究[J].中国新药杂志, 2004, 13(6): 548-53.]
|
| [5] |
Yang L, Wang JW, Cui CX, et al. Rh-endostatin(YH-16) in combination with vinorelbine and cisplatin for advanced non-small cell lung cancer: a multicenter phase Ⅱ trial[J].Zhongguo Xin Yao Za Zhi, 2005, 14(2): 204-7.[杨林, 王金万, 崔成旭, 等. 重组人血管 内皮抑制素YH-16联合用药治疗晚期非小细胞肺癌的多中心Ⅱ 期临床试验[J]. 中国新药杂志, 2005, 14(2): 204-7.]
|
| [6] |
Wang JW, Sun Y, Liu YY, et al. Results of randomized, multicenter, double-blind phase III trial of rh-endostatin(YH-16) in treatment of advanced non-small cell lung cancer patients[J]. Zhongguo Fei Ai Za Zhi, 2005, 8(4): 283-90.[王金万, 孙燕, 刘永煜, 等. 重组人血管 内皮抑素联合NP方案治疗晚期NSCLC随机、双盲、对照、多中 心Ⅲ期临床研究[J]. 中国肺癌杂志，2005, 8(4): 283-90.]
|
| [7] |
Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer[J]. J Clin Oncol, 20 04, 22(11): 2184-91.
|
| [8] |
Lu S, Zhu JQ. Assessment of the efficacy and safety of bevacizumab plus carboplatin and paclitaxel in patients with non-small cell lung cancer[J]. Xun Zheng Yi Xue, 2006, 6(4): 211-2, 237.[陆舜, 朱建权. 贝伐单抗联合卡铂加紫杉醇在非小细胞肺癌中的疗效与安全性 评价[J] 循证医学, 2006, 6(4): 211-2, 237.]
|
| [9] |
Reck M, von Pawel J, Zatloukal P, et al. Phase Ⅲ trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil[J]. J Clin Oncol, 2009, 27(8): 1227-34.
|
| [10] |
Reck M, von Pawel J, Zatloukal P, et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase Ⅲ trial (AVAiL)[J]. Ann Oncol, 2010, 21(9): 18 04-9.
|
| [11] |
Sun JF, Wu RR, Norris C, et al. Safety of chronic low-dose capecitabine as maintenance therapy in gastrointestinal cancers[J]. Gastrointest Cancer Res, 2009, 3(4): 134-40.
|
| [12] |
Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer[J].N Engl J Med, 20 06, 355(24): 2542-50.
|
| [13] |
Reynolds C, Barrera D, Jotte R, et al. Phase Ⅱ trial of nanoparticle albumin-bound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancer[J]. J Thorac Oncol, 2009, 4(12): 1537-43.
|
| [14] |
Wang T, Luo LL. A systematic review of bevacizumab for nonsmall lung caner[J]. Zhongguo Shi Yong Yi Yao,2008, 3(5): 1-2. [王 艇, 罗黎力. 贝伐单抗治疗晚期非小细胞肺癌的系统评价[J]. 中 国实用医药, 2008, 3(5): 1-2.]
|
| [15] |
Manegold C, von Pawel J, Zatloukal P, et al. Randomised, doubleblind multicentre phase Ⅲ study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naive patients with advanced or recurrent non-squamous non-small cell lung cancer(NSCLC): BO17704[J]. J Clin Oncol,2007, 25(18S): LBA7514.
|
下载:
